Skip to main content
Premium Trial:

Request an Annual Quote

GenMark Files $150M Shelf Registration

NEW YORK (GenomeWeb News) – GenMark Diagnostics has filed a shelf registration with the US Securities and Exchange Commission to offer from time to time up to $150 million of its stock and/or other securities.

Proceeds from any sale of its securities will go toward general corporate purposes, such as R&D, license or technology acquisitions, menu expansion, and the development of the company's products, GenMark said. Proceeds may also be used for sales and marketing initiatives, commercial expansion, as well as general administrative expenses, working capital, and capital expenditures.

Aside from its common stock, other forms of securities the company may offer include warrants, preferred stock, and debt securities, according to its Form S-3 filed today.

GenMark is based in Carlsbad, Calif., and went public in the US in 2010. It develops molecular diagnostic assays and instruments, and last week reported a sharp increase in fourth-quarter revenues to $9.4 million.

Last June the company raised about $39.3 million in a public offering of its shares.

In afternoon trading on the Nasdaq, shares of GenMark were down around 4 percent at $11.56.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.